Skip to content

Clinical study on efficacy and safety of Huangqi Guizhi Wuwu decoction bubble bag in paclitaxel related peripheral neuritis of breast cancer patients : A protocol for a randomized, controlled, double-blind trial

Clinical study on efficacy and safety of Huangqi Guizhi Wuwu decoction bubble bag in paclitaxel related peripheral neuritis of breast cancer patients : A protocol for a randomized, controlled, double-blind trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006006
Enrollment
Unknown
Registered
2022-05-14
Start date
2022-05-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

control group:Routine nursing measures were given, that is, health education combined with vitamin E milk and vitamin B12 ointment.
Test group:On the basis of the control group, Huangqi Guizhi Wuwu decoction was used to soak hands and feet.

Sponsors

National Cancer Center, Chinese Academy of Medical Sciences / Cancer Hospital of Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ????????????????;???18-70?;???????????????????:????????,?????,??????,??????;???????3????;?????????????;???????,??????? ????????????????;???18-70?;???????????????????:????????,?????,??????,??????;???????3????;?????????????;???????,??????? (1) breast cancer patients confirmed by histology or pathology; ? Age 18-70 years old; ? Plan to receive or have received paclitaxel drugs: including solvent paclitaxel, docetaxel, albumin paclitaxel, paclitaxel liposome; ? The estimated survival time is more than 3 months; ? It conforms to the category of syndrome differentiation and treatment of blood arthralgia in traditional Chinese medicine; The patient is unconscious and can communicate with normal language

Exclusion criteria

Exclusion criteria: ? Age 70 years old; ? Peripheral neuropathy caused by other reasons; ? There are heart, liver and kidney insufficiency, cardiovascular disease and endocrine disease; Accompanied by mental and consciousness disorders; Severe skin disease and systemic infection; ? The patient was involuntary.

Design outcomes

Primary

MeasureTime frame
Evaluation scale of peripheral neurotoxicity of chemotherapeutic drugs (EORTC qlq-cipn20);Mental state rating scale;Score of TCM syndrome integral quantitative scale (slefi);

Countries

China

Contacts

Public ContactZhao Fang

National Cancer Center, Chinese Academy of Medical Sciences / Cancer Hospital of Peking Union Medical College

13671210227@126.com13671210227

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026